BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 2122730)

  • 1. Polycystic ovary syndrome: abnormalities and management with pulsatile gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.
    Filicori M; Flamigni C; Campaniello E; Meriggiola MC; Michelacci L; Valdiserri A; Ferrari P
    Am J Obstet Gynecol; 1990 Nov; 163(5 Pt 2):1737-42. PubMed ID: 2122730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
    Filicori M; Flamigni C; Campaniello E; Valdiserri A; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A
    J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
    Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
    J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypogonadotropic patients with ultrasonographically detected polycystic ovaries: endocrine response to pulsatile gonadotropin-releasing hormone.
    Schachter M; Balen AH; Patel A; Jacobs HS
    Gynecol Endocrinol; 1996 Oct; 10(5):327-35. PubMed ID: 8915662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined use of gonadotropin-releasing hormone and its analogues for ovulation induction optimization.
    Filicori M
    Clin Obstet Gynecol; 1993 Sep; 36(3):737-43. PubMed ID: 8403620
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of combined exogenous gonadotropins and pulsatile gonadotropin-releasing hormone in patients with polycystic ovarian disease: a new approach to induction of ovulation.
    Venturini PL; Remorgida V; Anserini P; De Cecco L
    Gynecol Endocrinol; 1988 Sep; 2(3):205-13. PubMed ID: 3147583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjusting the dose to the individual response of the patient during the induction of ovulation with pulsatile gonadotropin-releasing hormone.
    Mais V; Melis GB; Strigini F; Antinori D; de Ruggiero A; Fioretti P
    Fertil Steril; 1991 Jan; 55(1):80-5. PubMed ID: 1898894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovulation induction with pulsatile luteinizing releasing hormone in women with clomiphene citrate-resistant polycystic ovary-like disease: clinical results.
    Burger CW; Korsen TJ; Hompes PG; van Kessel H; Schoemaker J
    Fertil Steril; 1986 Dec; 46(6):1045-54. PubMed ID: 3096792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulsatile gonadotrophin releasing hormone stimulation after medium-term pituitary suppression in polycystic ovary syndrome.
    Scheele F; Hompes PG; van der Meer M; Schoute E; Schoemaker J
    Hum Reprod; 1993 Nov; 8 Suppl 2():197-9. PubMed ID: 8276960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of combined exogenous gonadotropins and pulsatile gonadotropin-releasing hormone in patients with polycystic ovarian disease.
    Remorgida V; Venturini PL; Anserini P; Salerno E; de Cecco L
    Fertil Steril; 1991 Jan; 55(1):61-5. PubMed ID: 1898892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovulation induction with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression by gonadotropin releasing hormone agonist in polycystic ovary disease. A cross-over study.
    Fulghesu AM; Lanzone A; Guida C; Nicoletti MC; Rossi P; Le Donne M; Caruso A; Mancuso S
    J Reprod Med; 1992 Oct; 37(10):834-40. PubMed ID: 1479563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of LHRH-A pretreatment in ovulation induction, using pulsatile administration of GnRH, in patients with polycystic ovaries].
    D'Amato G; Vizziello G; Fanizza G
    Minerva Ginecol; 1992 May; 44(5):257-62. PubMed ID: 1608524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of subcutaneous and intravenous pulsatile gonadotropin releasing hormone in polycystic ovary disease.
    Saffan DS; Seibel MM
    J Reprod Med; 1992 Jun; 37(6):545-51. PubMed ID: 1619610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovulation induction with pulsatile luteinizing hormone-releasing hormone in women with clomiphene citrate-resistant polycystic ovary-like disease: endocrine results.
    Burger CW; Hompes PG; Korsen TJ; Schoemaker J
    Fertil Steril; 1989 Jan; 51(1):20-9. PubMed ID: 2491993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovulation induction with subcutaneous pulsatile gonadotropin-releasing hormone in various ovulatory disorders.
    Saffan D; Seibel MM
    Fertil Steril; 1986 Apr; 45(4):475-82. PubMed ID: 3082681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome.
    Timmerman-van Kessel EC; Cikot RJ; Dargel-Donkers EJ; Zwertbroek W; van Dop PA; Schoot DC
    Fertil Steril; 2000 Jun; 73(6):1145-8. PubMed ID: 10856472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection.
    Santoro N
    Am J Obstet Gynecol; 1990 Nov; 163(5 Pt 2):1759-64. PubMed ID: 2122733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
    Blankstein J; Rabinovici J; Goldenberg M; Shaley J; Mehta A; Serr DM; Mashiach S
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.